Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...
Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drugs
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for ...